A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Neuromyelitis optica
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVENT
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
    • 06 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
    • 26 Oct 2017 According to an Alexion Pharmaceuticals media release, the company expects to report data in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top